On September 11, 2009, Ahrendt, Kateri A.; Buckmelter, Alexandre J.; De Meese, Jason; Grina, Jonas; Hansen, Joshua D.; Laird, Ellen R.; Lunghofer, Paul; Moreno, David; Newhouse, Brad; Ren, Li; Seo, Jeongbeob; Tian, Hongqi; Wenglowsky, Steven Mark; Feng, Bainian; Gunzner, Janet; Malesky, Kim; Mathieu, Simon; Rudolph, Joachim; Wen, Zhaoyang; Young, Wendy B. published a patent.Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine The title of the patent was N-Pyrazolo[3,4-b]pyridinyl benzamide derivatives as Raf inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:
Compounds of formula I are useful for inhibition of Raf kinases. Methods of using compounds of formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo prevention or treatment of Raf-mediated disorders in mammalian cells, or associated pathol. conditions are disclosed. Compounds of formula I wherein R1 and R2 are independently H, halo, CN, C1-3 alkyl and C1-3 alkoxy; R3 is H, halo and C1-3 alkyl; R4 is C3-5 cycloalkyl, C1-6 alkyl, C2-6 alkenyl, etc.; R5 is H, halo, CN, NH2 and derivatives, etc.; and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cyclization of 1H-pyrazol-5-amine with 2-bromomalonaldehyde; the resulting 5-bromo-1H-pyrazolo[3,4-b]pyridine underwent alkylation with 2-(trimethylsilyl)ethoxymethyl chloride to give 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine, which underwent cross-coupling with tert-Bu carbamate to give tert-Bu 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-5-ylcarbamate, which underwent hydrolysis to give 1H-pyrazolo[3,4-b]pyridin-5-amine, which underwent amidation with 2.6-difluoro-3-(propylsulfonamido)benzoic acid to give compound II. All the invention compounds were evaluated for their Raf inhibitory activity. From the assay, it was determined that compound II along with the other example compound exhibited IC50 values of less than 1 μM. The experimental process involved the reaction of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine(cas: 1186608-73-0).Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine
The Article related to pyrazolopyridinyl benzamide preparation raf inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Reference of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics